As a follow on to the potential of 27mer DsiRNAs as a key platform for drug discovery and development, we are happy to report:
Dicerna Pharmaceuticals, a Second Generation RNA Interference Company, Completes Second Closing of Series A Financing; Unveils Strategic Focus
Dicerna Pharmaceuticals, Inc. (www.dicerna.com), an RNA interference company developing novel therapeutics utilizing proprietary Dicer Substrate Technology™, today announced a second closing of its Series A financing, receiving a total of $8.4 million in additional venture capital from new investor Abingworth and existing investors Oxford Bioscience Partners and Skyline Ventures. With this additional capital, Dicerna has completed a $21.4 million Series A financing round. Pursuant to this second closing, Vincent J. Miles, Ph.D., venture partner at Abingworth has joined Dicerna’s board of directors. Prior to Abingworth, Dr. Miles was senior vice president of business development at Alnylam Pharmaceuticals, an Abingworth portfolio company. Read entire press release.
We will continue to keep you updated on the Dicerna Story.